HEALY JAMES
SEC CIK 1245624 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc. | Dir | 2.73M | — | — | 1 | 2026-05-04 | 2026-05-04 |
| NTRA | Natera, Inc. | Dir | 46.3K | $271.2K | $37.93M | 19 | 2021-07-22 | 2025-04-25 |
| BIOA | BioAge Labs, Inc. | Dir | 1.64M | $12.00M | — | 2 | 2024-09-27 | 2024-09-27 |
| RAPP | Rapport Therapeutics, Inc. | Dir | 33.6K | $10.58M | — | 3 | 2024-06-10 | 2024-07-01 |
| AVBP | ArriVent BioPharma, Inc. | Dir | 1.25M | $8.00M | — | 2 | 2024-01-30 | 2024-01-30 |
| CHRS | Coherus Oncology, Inc. | Dir | 334.4K | — | $7.25M | 1 | 2021-09-27 | 2021-09-27 |
Most active insiders at SPTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ARCH Venture Partners XII, LLC | 10% | $19.80M | — |
| 2 | HOMBACH ROBERT J. | Dir | $235.8K | — |
| 3 | Chen Michael Cunyuan | CSO | — | — |
| 4 | Gladstein Lana | GC | — | — |
| 5 | White Lauren | CFO | — | — |
| 6 | Torres Denice | Dir | — | — |
| 7 | Loebel Antony | Chief Medical Off | — | — |
| 8 | PureTech Health plc | 10% | — | — |
| 9 | HEALY JAMES | Dir | — | — |
| 10 | PAUL STEVEN M | Dir | — | — |
Transactions 28
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-05-04 18:14 | 2026-05-04 | SPTX | Seaport Therapeutics, Inc. | HEALY JAMES | Dir | C - Cnv Deriv | — | +2.73M | 2.73M | New | — |
| 2025-04-29 | 2025-04-25 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | — | +142 | 46.3K | +0.3% | — | |
| 2025-02-04 | 2025-01-31 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | — | +114 | 46.1K | +0.2% | — | |
| 2024-10-29 | 2024-10-25 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | — | +153 | 46.0K | +0.3% | — | |
| DI | 2024-09-27 | 2024-09-27 | BIOA | BioAge Labs, Inc. | HEALY JAMES | Dir | C - Cnv Deriv | — | +1.64M | 1.64M | New | — |
| DMI | 2024-09-27 | 2024-09-27 | BIOA | BioAge Labs, Inc. | HEALY JAMES | Dir | P - Purchase | $18.00 | +666.7K | 11.1K | New | +$12.00M |
| 2024-07-30 | 2024-07-26 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | — | +177 | 45.9K | +0.4% | — | |
| MI | 2024-07-03 | 2024-07-01 | RAPP | Rapport Therapeutics, Inc. | HEALY JAMES | Dir | P - Purchase | $24.52 | +44.0K | 33.6K | New | +$1.08M |
| 2024-07-02 | 2024-06-28 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | — | +2,964 | 45.7K | +7% | — | |
| DMI | 2024-06-10 | 2024-06-10 | RAPP | Rapport Therapeutics, Inc. | HEALY JAMES | Dir | P - Purchase | $17.00 | +558.8K | 17.9K | New | +$9.50M |
| DI | 2024-06-10 | 2024-06-10 | RAPP | Rapport Therapeutics, Inc. | HEALY JAMES | Dir | C - Cnv Deriv | $0.00 | +1.39M | 1.39M | New | $0 |
| 2024-04-30 | 2024-04-26 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | — | +210 | 42.7K | +0.5% | — | |
| DI | 2024-01-31 | 2024-01-30 | AVBP | ArriVent BioPharma, Inc. | HEALY JAMES | Dir | C - Cnv Deriv | — | +1.25M | 1.25M | New | — |
| DI | 2024-01-31 | 2024-01-30 | AVBP | ArriVent BioPharma, Inc. | HEALY JAMES | Dir | P - Purchase | $18.00 | +444.4K | 1.70M | +35% | +$8.00M |
| 2024-01-30 | 2024-01-26 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | $63.79 | +264 | 42.5K | +0.6% | +$16.8K | |
| I | 2023-12-22 | 2023-12-13 | NTRA | Natera, Inc. | HEALY JAMES | Dir | S - Sale | $58.75 | -644.0K | 0 | -100% | -$37.84M |
| 2023-10-31 | 2023-10-27 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | $42.60 | +396 | 42.2K | +0.9% | +$16.9K | |
| 2023-08-01 | 2023-07-28 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | $48.48 | +328 | 41.8K | +0.8% | +$15.9K | |
| D | 2023-07-05 | 2023-06-30 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | — | +2,750 | 41.5K | +7% | — |
| D | 2023-05-30 | 2023-05-25 | NTRA | Natera, Inc. | HEALY JAMES | Dir | M - OptEx | — | +3,534 | 38.8K | +10% | — |
| 2023-04-18 | 2023-04-14 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | $54.73 | +285 | 35.2K | +0.8% | +$15.6K | |
| 2023-01-18 | 2023-01-13 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | $40.01 | +390 | 34.9K | +1% | +$15.6K | |
| I | 2023-01-18 | 2022-11-16 | NTRA | Natera, Inc. | HEALY JAMES | Dir | S - Sale | $37.71 | -2,400 | 0 | -100% | -$90.5K |
| 2022-10-18 | 2022-10-14 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | $45.42 | +344 | 34.6K | +1% | +$15.6K | |
| A | 2022-09-02 | 2022-07-08 | NTRA | Natera, Inc. | HEALY JAMES | Dir | A - Grant | $0.00 | +430 | 34.2K | +1% | $0 |
| D | 2022-05-27 | 2022-05-25 | NTRA | Natera, Inc. | HEALY JAMES | Dir | M - OptEx | — | +1,307 | 33.8K | +4% | — |
| MI | 2021-09-29 | 2021-09-27+ | CHRS | Coherus Oncology, Inc. | HEALY JAMES | Dir | S - Sale | $16.68 | -434.6K | 334.4K | -57% | -$7.25M |
| I | 2021-07-26 | 2021-07-22 | NTRA | Natera, Inc. | HEALY JAMES | Dir | P - Purchase | $113.00 | +2,400 | 2,400 | New | +$271.2K |
Purchase Sale Sale after option exercise All abbreviations